Skip to main content
SpringerLink
Log in

CD7 aberrant expression led to a lineage switch at relapsed childhood acute pre-B lymphoblastic leukemia

  • Case Report
  • Published:
Medical Molecular Morphology Aims and scope Submit manuscript

Abstract

Immunophenotypic changes and lineage switch between diagnosis and relapse in acute lymphoblastic leukemia are uncommon and accompanied by poor outcomes. In this report, a 12-year-old boy with diagnosis of pre-B ALL with an aberrant expression of CD 7 is described. Patient was treated with the ALL-BFM 2000 protocol and suffered an episode of relapse with a lineage switch from pre-B ALL to T cell ALL. This report concludes that presence of aberrant expression of CD7 at diagnosis of pre-B ALL can have prognostic value of lineage switch to T cell ALL at relapse.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Lanzkowsky P (2011) Manual of hematology and oncology. Elsevier, United States of America

    Google Scholar 

  2. Han X, Bueso-Ramos CE (2007) Precursor T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma and acute biphenotypic leukemias. Am J Clin Pathol 127:528–544

    Article  CAS  PubMed  Google Scholar 

  3. Jaffe ES, Harris NL, Vardiman JW, Campo E, Arber DA (2010) Hematopathology. Saunders, Philadelphia, p 1072

    Google Scholar 

  4. Matutes E, Morilla R, Farahat N, Carbonell F, Swansbury J, Dyer M, Catovsky D (1997) Definition of acute biphenotypic leukemia. Haematologica 82:64–66

    CAS  PubMed  Google Scholar 

  5. Henze G, Fengler R, Hartmann R, Kornhuber B, Janka-Schaub G, Niethammer D, Riehm H (1991) Six-year experience with a comprehensive approach to the treatment of recurrent childhood acute lymphoblastic leukemia (ALL-REZ BFM 85). A relapse study of the BFM group. Blood 78:1166–1172

    CAS  PubMed  Google Scholar 

  6. Reiter A, Schrappe M, Ludwig W-D, Hiddemann W, Sauter S, Henze G, Zimmermann M, Lampert F, Havers W, Niethammer D (1994) Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood 84:3122–3133

    CAS  PubMed  Google Scholar 

  7. Van Wering E, Beishuizen A, Roeffen E, Van Der Linden-Schrever B, Verhoeven M, Hählen K, Hooijkaas H, Van Dongen J (1995) Immunophenotypic changes between diagnosis and relapse in childhood acute lymphoblastic leukemia. Leukemia 9:1523–1533

    PubMed  Google Scholar 

  8. Guglielmi C, Cordone I, Boecklin F, Masi S, Valentini T, Vegna M, Ferrari A, Testi A, Foa R (1997) Immunophenotype of adult and childhood acute lymphoblastic leukemia: changes at first relapse and clinico-prognostic implications. Leukemia 11:1501–1507

    Article  CAS  PubMed  Google Scholar 

  9. Rossi JG, Bernasconi AR, Alonso CN, Rubio PL, Gallego MS, Carrara CA, Guitter MR, Eberle SE, Cocce M, Zubizarreta PA (2012) Lineage switch in childhood acute leukemia: an unusual event with poor outcome. Am J Hematol 87:890–897

    Article  PubMed  Google Scholar 

  10. Raghavachar A, Thiel E, Bartram CR (1987) Analyses of phenotype and genotype in acute lymphoblastic leukemias at first presentation and in relapse. Blood 70:1079–1083

    CAS  PubMed  Google Scholar 

  11. Moradi-Lakeh M, Esteghamati A (2013) National Immunization Program in Iran: whys and why nots. Hum Vaccin Immunother 9:112–114

    Article  PubMed  PubMed Central  Google Scholar 

  12. Möricke A, Zimmermann M, Reiter A, Henze G, Schrauder A, Gadner H, Ludwig W, Ritter J, Harbott J, Mann G (2010) Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia 24:265–284

    Article  PubMed  Google Scholar 

  13. Schorin MA, Blattner S, Gelber RD, Tarbell NJ, Donnelly M, Dalton V, Cohen HJ, Sallan SE (1994) Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber Cancer Institute/Children’s Hospital Acute Lymphoblastic Leukemia Consortium Protocol 85-01. J Clin Oncol 12:740–747

    CAS  PubMed  Google Scholar 

  14. Park M, Koh KN, Kim BE, Im HJ, Jang S, Park CJ, Chi HS, Seo JJ (2011) Lineage switch at relapse of childhood acute leukemia: a report of four cases. J Korean Med Sci 26:829–831

    Article  PubMed  PubMed Central  Google Scholar 

  15. Pui C-H, Raimondi SC, Behm FG, Ochs J, Furman WL, Bunin NJ, Ribeiro RC, Tinsley PA, Mirro J (1986) Shifts in blast cell phenotype and karyotype at relapse of childhood lymphoblastic leukemia [published erratum appears in Blood 1987 Mar; 69 (3): 996]. Blood 68:1306–1310

    CAS  PubMed  Google Scholar 

  16. Abshire T, Buchanan G, Jackson J, Shuster J, Brock B, Head D, Behm F, Crist W, Link M, Borowitz M (1992) Morphologic, immunologic and cytogenetic studies in children with acute lymphoblastic leukemia at diagnosis and relapse: a Pediatric Oncology Group study. Leukemia 6:357–362

    CAS  PubMed  Google Scholar 

  17. Cruse JM, Lewis RE, Pierce S, Lam J, Tadros Y (2005) Aberrant expression of CD7, CD56, and CD79a antigens in acute myeloid leukemias. Exp Mol Pathol 79:39–41

    Article  CAS  PubMed  Google Scholar 

  18. Rausei-Mills V, Chang KL, Gaal KK, Weiss LM, Huang Q (2008) Aberrant expression of CD7 in myeloblasts is highly associated with de novo acute myeloid leukemias with FLT3/ITD mutation. Am J Clin Pathol 129:624–629

    Article  CAS  PubMed  Google Scholar 

  19. Hussein S, Gill KZ, Sireci AN, Colovai AI, Small T, Emmons FN, Murty VV, Bhagat G, Alobeid B (2011) Aberrant T-cell antigen expression in B lymphoblastic leukaemia. Br J Haematol 155:449–456

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

Mahak’s research team sends their gratitude to all colleagues for their helpful discussions.

Author information

Authors and Affiliations

  1. Research Department, Mahak’s Pediatric Cancer Treatment and Research Center, Mahak Blvd., Oshan Blvd., Aghdasieh Ave, 1956993461, Tehran, Iran

    Vahid Fallah Azad, Amir Abbas Hedayati Asl, Naghmeh Niktoreh Mofrad & Mansoureh Haghighi

  2. Mahak’s Pediatric Cancer Treatment and Research Center, Islamic Azad University of Qom, Qom, Iran

    Maryam Tashvighi

  3. Mahak’s Pediatric Cancer Treatment and Research Center, Army Medical Science University, Tehran, Iran

    Azim Mehrvar

Authors
  1. Vahid Fallah Azad
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Amir Abbas Hedayati Asl
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Maryam Tashvighi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Naghmeh Niktoreh Mofrad
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mansoureh Haghighi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Azim Mehrvar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Naghmeh Niktoreh Mofrad.

Ethics declarations

Conflict of interest

The authors reported no potential conflicts of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fallah Azad, V., Hedayati Asl, A.A., Tashvighi, M. et al. CD7 aberrant expression led to a lineage switch at relapsed childhood acute pre-B lymphoblastic leukemia. Med Mol Morphol 49, 53–56 (2016). https://doi.org/10.1007/s00795-015-0117-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00795-015-0117-0

Keywords

Search

Navigation